SCHEMBL3764873

SCHEMBL3764873

Cc1c(-c2ccccc2)[c]ncc1NC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 1/20 0.47
CNR2 P34972 1/20 0.40
ELANE P08246 1/20 0.39
CTRB1 P17538 1/20 0.39
CKS1B P61024 2/20 0.39
SKP1 P63208 2/20 0.39
SKP2 Q13309 2/20 0.39
BRD4 O60885 1/20 0.38
P2RX7 Q99572 1/20 0.38
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
IDO1 P14902 1/20 0.37
LCK P06239 1/20 0.37
NAMPT P43490 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
METAP1 P53582 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3757741 0.81 ALDH1A1 (0.44) MEN1NPC1RAB9AKMT2ARXFP1
SCHEMBL3767247 0.79 CKS1B (0.41) BRD9CNR2CKS1BSKP1SKP2
SCHEMBL3755044 0.79 BRD9 (0.40) BRD9CNR2CKS1BSKP1SKP2
SCHEMBL3766617 0.78 BRD9 (0.40) BRD9CNR2CKS1BSKP1SKP2
SCHEMBL2880194 0.72 BRD9 (0.52) BRD9CNR2ELANECTRB1BRD4
SCHEMBL2880191 0.71 LMNA (0.54) BRD9CNR2BRD4MEN1NPC1
SCHEMBL28444082 0.71 CHRM3 (0.52) BRD9MEN1KMT2ALMNA
SCHEMBL16592378 0.71 NTRK1 (0.69) BRD9CKS1BSKP1SKP2
SCHEMBL15756222 0.71 BRD9 (0.56) BRD9CNR2CKS1BSKP1SKP2
SCHEMBL17131179 0.71 BRD9 (0.50) BRD9CNR2CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA BRD9 938/4885CNR2 3147/4885ELANE 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.